Biotech improving delivery of macromolecule cancer therapeutics.
| Date | Round | Amount |
|---|---|---|
| Oct 2021 | Series A Utrecht biotech Sapreme Technologies raised a EUR 15M Series A led by Aglaia Oncology Funds. | $17.7M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.